Inception 2 Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inception 2 Inc.
Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.
Versant Ventures Looks To Canada, Europe For New Deals
Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”
Biopharma Dealmaking Quarterly Statistics, Q4 2012
At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.
NeXeption, Not The Rule: Another Twist On Asset-Based Financing
As VCs experiment with new models for single-asset companies, new entrant NeXeption is trying something similar without raising its own fund. Can it wring enough value from the best assets pharmas are neglecting, without giving too much back to their original owners?
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.